Results 221 to 230 of about 302,337 (268)

Accuracy of intestinal ultrasonography in the evaluation of patients with moderate-to-severe ulcerative colitis starting infliximab therapy

Ahmad Albshesh
openalex   +1 more source

Characterization of pediatric eosinophilic gastrointestinal disorders beyond eosinophilic esophagitis in a nationwide cohort

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Nonesophageal eosinophilic gastrointestinal disorders (non‐EoE EGIDs) are rare, underrecognized inflammatory diseases of the gastrointestinal (GI) tract, especially in children. Their clinical heterogeneity and lack of specific biomarkers contribute to diagnostic delays and therapeutic challenges.
Sara Renzo, Luca Scarallo, Selene Del Vespa, Giulia Angelino, Matteo Bramuzzo, Enrico Felici, Flavio Labriola, Francesca Laganà, Lorenzo Norsa, Salvatore Oliva, Marisa Piccirillo, Elena Pozzi, Francesca Rea, Giusy Russo, Francesco Valitutti, Giovanna Zuin, Paolo Lionetti   +16 more
wiley   +1 more source

New-onset ulcerative colitis temporally associated with with ixekizumab in a psoriasis patient successfully treated with guselkunmab: A case report. [PDF]

Medicine (Baltimore)
Tang J, Li W, Zhang H.
europepmc   +1 more source

Therapy de‐escalation in pediatric patients with inflammatory bowel disease in remission: Data analysis from the CEDATA registry

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives There are no standardized criteria about stepping down from combination therapy (immunomodulator and tumor necrosis factor (TNF)‐alpha‐inhibitors) in children with inflammatory bowel disease (IBD) to reduce risk for side effects. Our aim was to describe how de‐escalation has been performed in a large pediatric cohort and to find ...
Sila Cekin, Christoph Huenseler, Serdar Cantez, Ilse Broekaert, Jan de Laffolie, CEDATA‐GPGE® Study Group   +5 more
wiley   +1 more source

Brevilin A reverses colitis of inflammatory bowel disease via modulation of TNF-α signaling and microbiome dysregulation. [PDF]

Gut Pathog
Chen L, Tang C, Hu D, Yu S, Liao P.
europepmc   +1 more source

Insights into the treatment of infliximab and vedolizumab in positive PR3-ANCA patients with moderately to severely active ulcerative colitis: multicenter real-world evidence

Qi Yu, Yiyu Cheng, Fang Liu, Yidong Chen, Jiamin Li, Xiao‐Peng Zhang, Xiaoyu Fu, Junrong Li, Liangru Zhu   +8 more
openalex   +1 more source

Using machine learning to predict clinical remission with exclusive enteral nutrition in pediatric Crohn disease

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Exclusive enteral nutrition (EEN) is a first‐line treatment for induction of remission in luminal pediatric Crohn disease (pCD). However, as the efficacy of EEN varies from patient to patient, there is a need to distinguish between responders and nonresponding patients. This study had two aims.
Ricardo G. Suarez Suarez, Daniel G. McClement, Roberto Vega, Hien Q. Huynh, Ayub Shaikh, Anthony Otley, Kevan Jacobson, Mary Sherlock, David R. Mack, Colette Deslandres, Wael El‐Matary, Eileen Crowley, Jennifer deBruyn, Thomas Walters, Anne M. Griffiths, Russell Greiner, Eytan Wine, The Canadian Children IBD Network, Jeff Critch, Lara Hart, Rilla Schneider, Kevin Bax, Eric I. Benchimol   +22 more
wiley   +1 more source

S1612 Comparative Impact of Low-Dose Aspirin Alone vs Aspirin Plus Rifaximin on Colorectal Cancer Risk in Ulcerative Colitis With Dysplasia

Anqi Luo, Allen Seylani, Yohannes Haile, Assal Sadighian, Sadaf Sadighian   +4 more
openalex   +1 more source

Methotrexate toxicity and intolerance in paediatric inflammatory bowel disease: A retrospective cohort study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Methotrexate (MTX) is frequently prescribed in paediatric inflammatory bowel disease (IBD), with routine laboratory monitoring to detect adverse events (AEs), such as hepatotoxicity and myelotoxicity. However, data on the incidence and predictors of these AEs remain limited.
Eva Vermeer, Eveline L. Soetens, Eduard A. Struys, Johan E. van Limbergen, Maja Bulatović‐Ćalasan, Robert de Jonge, Nanne K. H. de Boer, Tim G. J. de Meij   +7 more
wiley   +1 more source

When checkpoint inhibitors break barriers: Mechanisms and challenges of irAEs of the skin, gastrointestinal tract, and lung. [PDF]

Clin Cancer Res
Sinha A, Seervai RNH, Vlastelica KM, Fisher Thomas M, Hornick NI.   +4 more
europepmc   +1 more source